Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
labff · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Laboratorios Farmaceuticos Rovi, S.A. (LABFF) measures how much investors pay for each dollar of the company's trailing earnings. LABFF's current PE ratio of 22.60x is calculated by dividing its stock price of $90.61 by its TTM earnings per share of $2.58. +2.6% elevated vs 5Y avg 22.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%85.2x
MedianQ3 · 75%371.1x
Max
At 22.60x, LABFF's current P/E is lower than in 15% of its annual fiscal year readings over the past 20 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Laboratorios Farmaceuticos Rovi, S.A.You LABFF | $4.6B | 22.60x | -35.8% | $2.58 |
 ALK-Abelló A/S AKBLF | $6.3B | 42.58x | +21.0% | $5.39 |
 Camurus AB (publ) CAMRF | $3.5B | 49.84x | +41.7% | $12.42 |
 COSMOS Pharmaceutical Corporation CSMYF | $3.3B | 16.92x | -51.9% | $390.86 |
 Carl Zeiss Meditec AG CZMWF | $2.7B | 26.20x | -25.5% | $1.61 |
 Genscript Biotech Corporation GNNSF | $4.2B | N/A | — | -$0.25 |
 InnoCare Pharma Limited INCPF | $3.1B | 40.36x | +14.7% | $0.36 |
Industry Average 5 peers with valid PE | — | 35.18x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 28.10x | $2.74 | -14.3% | |
2024-12-31 FY2024 | 32.77x | $2.67 | +123.1% | |
2023-12-31 FY2023 | 14.69x | $3.20 | +15.0% | |
2022-12-31 FY2022 | 12.78x | $3.73 | -41.6% | |
2021-12-31 FY2021 | 21.88x | $2.76 | -40.5% | |
2020-12-31 FY2020 | 36.80x | $1.10 | -40.8% | |
2019-12-31 FY2019 | 62.12x | $0.71 | -49.8% | |
2018-12-31 FY2018 | 123.75x | $0.35 | +4.8% | |
2017-12-31 FY2017 | 118.12x | $0.35 | +33.5% | |
2016-12-31 FY2016 | 88.48x | $0.53 | -22.5% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Laboratorios Farmaceuticos Rovi, S.A. (LABFF) measures how much investors pay for each dollar of the company's trailing earnings. LABFF's current PE ratio of 22.60x is calculated by dividing its stock price of $90.61 by its TTM earnings per share of $2.58.
Frequently asked questions
LABFF pe ratio · 6 questionsLABFF's current PE ratio is 22.60x as of 2026-06-09, based on a stock price of $90.61 and TTM EPS of $2.58. Data sourced from Financial Modeling Prep via LABFF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Laboratorios Farmaceuticos Rovi, S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09